26 Jul 05
The antihypertensive market was valued at $31 billion in 2003. The kidney plays an important role in regulating blood pressure and the renal enzyme renin is a target for what is expected to be the next blockbuster class of anti-hypertensives. The report highlighted here identifies a further renal enzyme, renalase that may be another target for the treatment of hypertension.
21 Jul 05
Assaying therapeutic agents requires the availability of apparatus to dose experimental animals as well as to measure biological effect. Available dosing systems for inhalation agents are suboptimal generally causing stress to the animal as well as exposing the operator to potentially harmful agents. Texas based researchers have developed an improved system for the delivery of agents to the airway
18 Jul 05
Hepatitis C virus (HCV) infection produces cirrhosis, end-stage liver disease and liver cancer and by 2010 38,000 deaths will result from infection. Anemia associated with ribavirin, a common treatment of infected patients represents a major problem. Valeant Pharmaceutical have developed a prodrug of ribavirin, viramidine which is activated within the liver resulting in reduced levels of ribavirin accumulating in red blood cells thus overcoming the problem of anemia.
14 Jul 05
The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile
13 Jul 05
Anxiety disorders affect 20% of the total population across the seven major markets. Recent data demonstrates the efficacy of MPEP, the prototypical mGlu5 receptor antagonist as a an anxiolytic. Efficacy was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline
08 Jul 05
DailyUpdates was developed in 2002 by the drug development consultants, LeadDiscovery. Developed for the R&D community, 1,000's of individuals plus many of the top 20 pharmaceutical companies now use this simple yet effective tool to track key events in the drug discovery sector.
06 Jul 05
The field of histone deacetylase inhibitors is moving into a new phase of development. The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has now started to produce success in the clinic, particularly in the field of oncology. Over the next few years experts believe that as first generation HDAC inhibitors produce clinical benefits and second generation inhibitors are rationally designed with improved specificity
01 Jul 05
Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This report evaluates this exciting area of drug discovery
29 Jun 05
Welcome to the June edition of TherapeuticAdvances, LeadDiscovery's free newsletter for the drug development sector. Read on for editorial comment on selected studies recently featured on DailyUpdates our regular bulletin of breaking journal articles and drug development news
28 Jun 05
Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs. Current pipeline products are expected to account for 89% of total market sales by 2015, however other developmental antivirals are also expected to contribute significantly to future market growth, potentially resulting in new treatment paradigms.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.